CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...7172737475767778798081...39323933»
  • ||||||||||  Yutuo (zimberelimab) / Arcus Biosci, Gilead, etrumadenant (AB928) / Arcus Biosci, Gilead
    Trial completion date, Trial primary completion date:  ARC-4: A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (clinicaltrials.gov) -  Aug 1, 2024   
    P1,  N=77, Active, not recruiting, 
    Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024 Trial completion date: Aug 2024 --> Nov 2024 | Trial primary completion date: Aug 2024 --> Nov 2024
  • ||||||||||  FT576 / Fate Therap
    Enrollment closed, Enrollment change, Combination therapy, Monotherapy:  FT576 in Subjects With Multiple Myeloma (clinicaltrials.gov) -  Aug 1, 2024   
    P1,  N=31, Active, not recruiting, 
    N=150 --> 200 Recruiting --> Active, not recruiting | N=168 --> 31
  • ||||||||||  Review, Journal:  Diagnosis and management of Evans syndrome in adults: first consensus recommendations. (Pubmed Central) -  Aug 1, 2024   
    Finally, recommendations were given for supportive therapy, platelet or red blood cell transfusions, and thrombotic and antibiotic prophylaxis. These consensus-based recommendations should facilitate best practice for diagnosis and management of Evans syndrome in clinical practice.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Journal:  Daratumumab maintenance in patients with myeloma. (Pubmed Central) -  Aug 1, 2024   
    Epcoritamab monotherapy showed clinically meaningful activity in patients with multiply relapsed or refractory follicular lymphoma, and had a manageable safety profile. No abstract available
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Montelukast as a Rescue and Premedication for Rituximab Infusion Reactions. (Pubmed Central) -  Aug 1, 2024   
    Our results confirm D-VTd induction and consolidation as a standard of care, and support the option of subsequent daratumumab monotherapy maintenance, for transplant-eligible patients with newly diagnosed multiple myeloma. Rituximab (RTX) is a monoclonal antibody often used in patient treatment of malignancies and several rheumatological disorders, including vasculitides.1-3 It has become an essential component of many treatment protocols; however, is commonly associated with hypersensitivity infusion reactions.1.
  • ||||||||||  Rituxan (rituximab) / Roche
    Review, Journal, IO biomarker:  Overview and Diagnostic Approach in Autoimmune Neurology. (Pubmed Central) -  Aug 1, 2024   
    Autoimmune neurology is now a mainstream subspecialty, consisting of disorders with diverse presentations detectable using antibody testing of serum and CSF. Early and sustained immunotherapy (eg, corticosteroids, intravenous immunoglobulin [IVIg], plasma exchange) is recommended and may be supplemented by immune suppressants (eg, rituximab or cyclophosphamide) to sustain responses and optimize outcomes.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Tocilizumab Treatment in a Patient of Refractory Anti-EJ Positive ASyS: A Case Report. (Pubmed Central) -  Aug 1, 2024   
    The patients were resistant to various treatments, including rituximab (RTX), but benefited from TCZ. In this case, TCZ shows good therapeutic efficacy in a fatal acute exacerbation of ILD with a hyperinflammatory status, resulting in a relative remission of the disease flare and full preservation of lung function with a positive long-term treatment outcome.
  • ||||||||||  sunitinib / Generic mfg.
    Journal:  Design, development of pyrazole-linked spirocyclopropyl oxindole-carboxamides as potential cytotoxic agents and Type III allosteric VEGFR-2 inhibitors. (Pubmed Central) -  Aug 1, 2024   
    Sunitinib was rationally modified to spirocyclopropyloxindoline carboxamides and their in vitro cytotoxic profiling were evaluated...The qualitative assessment of apoptosis induction by 15w in MCF-7 cells was evaluated through AO/EB and DAPI staining studies, whereas apoptotic quantification and cell cycle analysis were performed through FACS analysis. The current study strives to sequentially optimize the structural attributes of 3-alkenyl oxindole core to surpass the existing challenges of well-known VEGFR-2 inhibitors and compound 15w was identified to be a prominent lead towards the development of clinical drug candidates.
  • ||||||||||  RGT-018 / Regor
    Journal:  Discovery of RGT-018: a Potent, Selective and Orally Bioavailable SOS1 Inhibitor for KRAS-driven Cancers. (Pubmed Central) -  Aug 1, 2024   
    FDA-approved sotorasib and adagrasib provide breakthrough therapies for cancer patients with KRASG12C mutation...Further enhanced anti-proliferation activity was observed when RGT-018 was combined with MEK, KRASG12C, EGFR or CDK4/6 inhibitors...Furthermore, RGT-018 overcame the resistance to the approved KRASG12C inhibitors caused by clinically acquired KRAS mutations either as a single agent or in combination. RGT-018 displayed promising pharmacological properties for combination with targeted agents to treat a broader KRAS-driven patient population.
  • ||||||||||  Review, Journal:  A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo. (Pubmed Central) -  Aug 1, 2024   
    Though there have been significant advancements in targeted therapies in skin diseases such as psoriasis or eczema, the progress in the treatment of vitiligo has been slow, with minimal studies assessing the effect of biologics, though there has been recent evidence of the effectiveness of JAK inhibition. This paper reviews the published case reports and studies for the use of systemic targeted therapies including biologics and JAK inhibitors in vitiligo.
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Hemophagocytic Lymphohistiocytosis (HLH) in an Elderly Male With Epstein-Barr Virus (EBV) Viremia. (Pubmed Central) -  Aug 1, 2024   
    The patient was promptly treated with steroids, rituximab, and etoposide; however, the patient's health continued to deteriorate, and he expired. This case highlights the challenges of early diagnosis of HLH in the elderly patient population due to large differentials, confounding comorbidities, and the rarity of the diagnosis in this age range.
  • ||||||||||  Yutuo (zimberelimab) / Arcus Biosci, Gilead
    PK/PD data, Journal, Metastases:  Population Pharmacokinetics and Exposure-Response Relationship of Zimberelimab in Chinese Patients with Advanced Tumors. (Pubmed Central) -  Aug 1, 2024   
    Toripalimab generates significant savings that enable budget-neutral funding for up to 17,533 [34,093] additional maintenance cycles over one year [two years] with toripalimab?+?pemetrexed in nonsquamous NSCLC, or 972 [973] full one-year [two-year] regimens. The exposure variables of zimberelimab have no obvious correlations with efficacy and safety, and 360
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Review, Journal:  Optimising salvage therapy for Hodgkin lymphoma: progress and future challenges. (Pubmed Central) -  Aug 1, 2024   
    Important themes have been recently explored in the first salvage setting including the recognition of the positive prognostic value of a negative pre-autologous stem cell transplantation (ASCT) FDG-PET response and the incorporation of novel agents such as brentuximab vedotin (BV) and immune checkpoint inhibitors (CPIs) as salvage regimens to improve patient outcomes...Achieving a complete remission by FDG-PET pre-ASCT is the most important prognostic factor in obtaining disease control and subsequent cure, and therefore should be a key goal of any salvage regimen. Although data from randomized controlled trials are currently lacking, retrospective evidence demonstrate superior event free survival with CPI-based regimens compared to conventional chemotherapy or BV based therapy.
  • ||||||||||  Truxima (rituximab-abbs) / Indukern, Teva, Mundipharma, Celltrion, Nippon Kayaku, Rituxan (rituximab) / Roche
    Journal:  Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus. (Pubmed Central) -  Aug 1, 2024   
    Except for the intravenous immunoglobulin administration rate, there were no differences in baseline characteristics between the two groups, and for the purpose of comparing efficacy, investigations into time to complete remission, total steroid intake to complete remission, and total steroid intake for 6?months following rituximab treatment revealed no significant differences between the two groups. Truxima can be considered a relatively affordable alternative treatment option for pemphigus, offering cost-effectiveness to patients who are indicated for the treatment with MabThera.
  • ||||||||||  CLN-617 / Cullinan Oncology
    Journal:  CLN-617 retains IL-2 and IL-12 in injected tumors to drive robust and systemic immune-mediated antitumor activity. (Pubmed Central) -  Aug 1, 2024   
    P1
    We found that IT administration of a murine surrogate of CLN-617, mCLN-617, eradicated established treated and untreated tumors in syngeneic models, significantly improved response to anti-PD1 checkpoint therapy, and generated a robust abscopal response dependent on cellular immunity and antigen cross-presentation. CLN-617 is being evaluated in a clinical trial in patients with advanced solid tumors (NCT06035744).